All Posts Tagged Tag: ‘GSK’

Lung Disease Drug Trials Point Toward Approval

GlaxoSmithKline (GSK) this week announced that phase III of trials for its new long-acting muscarinic antagonist/long-acting beta2 agonist (LAMA/LABA) drug are complete. The drug, which is administered via inhaler, is a once-daily medicine for treatment of chronic obstructive pulmonary disease (COPD), one of the most common forms of lung disease. The trials involved around 6,000 patients with COPD. The medication …

Read More